MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics


MeiraGTx Holdings plc - Ordinary Shares (MGTX): $6.38

0.07 (+1.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MGTX Stock Price Chart Interactive Chart >

Price chart for MGTX

MGTX Price/Volume Stats

Current price $6.38 52-week high $24.89
Prev. close $6.31 52-week low $5.70
Day low $6.20 Volume 144,600
Day high $6.39 Avg. volume 145,564
50-day MA $7.33 Dividend yield N/A
200-day MA $9.51 Market Cap 285.35M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio


MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.


MGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream


Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Piper Sandler 34th Annual Healthcare Conference (New York) Fireside Chat: Tuesday, November 29, 2022 at 8:30 a.m. ET Evercore ISI 5th Annual HealthCONx Conference (Virtual) Fireside Chat: Thursday, Decemb

Yahoo | November 22, 2022

MeiraGTx Holdings Third Quarter 2022 Earnings: Misses Expectations

MeiraGTx Holdings ( NASDAQ:MGTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.82m (down 31% from 3Q...

Yahoo | November 16, 2022

Time To Worry? Analysts Are Downgrading Their MeiraGTx Holdings plc (NASDAQ:MGTX) Outlook

Market forces rained on the parade of MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders today, when the analysts...

Yahoo | November 11, 2022

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkinson’s Disease -- Received $25.0 Million Investment from Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), the Investment Arm of Johnson and Johnson -- Company to Provide Clinical Program Update for the Phase 1 AQUAx Trial of AAV-hAQP1 for the Treatment of Gra

Yahoo | November 10, 2022

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo -6.45%
3-mo -28.31%
6-mo -21.53%
1-year -63.63%
3-year -69.96%
5-year N/A
YTD -73.13%
2021 56.80%
2020 -24.38%
2019 107.68%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5911 seconds.